Health knowledge made personal
Join this community!
› Share page:
Search posts:

Parvovirus B19 Vaccine

Posted May 06 2013 8:00pm

Description of Invention:
Parvovirus B19 (B19V) infection causes fifth disease, a disease characterized by rashes to the face and other parts of the body that primarily affects children. However, adults can also develop fifth disease and it can lead to more severe conditions. Patients that are immunocompromised, such as those who are HIV infected, organ transplant recipients, and cancer patients, can be particularly susceptible to more severe outcomes from B19V infection. Infection can also cause anemia and in pregnant women, it can lead to hydrops fetalis.

The subject technologies are expression vectors for the production of B19V VP1 and VP2 capsid proteins. Co-expression of the two proteins produce empty virus-like particles (VLPs) that can be used to develop a vaccine against parvovirus B19 and a packaging system for infectious B19V virus. Different expression vectors have been developed and optimized for expression in insects cells and more recently in mammalian cell lines such as 293, Cos7, Hela cells and 293T cells.

Vaccine against parvovirus B19V.

There is currently no B19V vaccine on the market.

Development Status:
  • Early-stage
  • Pre-clinical
  • Clinical
  • In vitro data available
  • In vivo data available (animal)
  • In vivo data available (human)

Neal S Young (NHLBI)
Sachiko Kajigaya (NHLBI)
Takashi Shimada (NHLBI)
Ning Zhi (NHLBI)

Patent Status:
HHS, Reference No. E-286-1988/2
US, , Patent No. 5,916,563, Issued 29 Jun 1999
US, , Patent No. 6,001,371, Issued 14 Dec 1999
US, , Patent No. 6,132,732, Issued 17 Oct 2000
US, , Patent No. 6,558,676, Issued 06 May 2003
US, Application No. 13/578,577 filed 10 Aug 2012

Relevant Publication:
  1. Bernstein DI, et al. [ PMID 21807052 ]
  2. Zhi N, et al. [ PMID 20943969 ]

Collaborative Research Opportunity:
The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the technology for producing Parvovirus B19 vaccine. For collaboration opportunities, please contact Cecilia Pazman, Ph.D. at .

For Licensing Information Please Contact:
Kevin Chang Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-435-5018
Fax: 301-402-0220

Ref No: 2560

Updated: 05/2013

Post a comment
Write a comment:

Related Searches